Optical coherence tomography (OCT) is a medical image modality that is used to capture, non-invasively, high-resolution cross-sectional images of the retinal tissue. These images constitute a suitable scenario for the diagnosis of relevant eye diseases like the vitreomacular traction or the diabetic retinopathy. The identification of the epiretinal membrane (ERM) is a relevant issue as its presence constitutes a symptom of diseases like the macular edema, deteriorating the vision quality of the patients. This work presents an automatic methodology for the identification of the ERM presence in OCT scans. Initially, a complete and heterogeneous set of features was defined to capture the properties of the ERM in the OCT scans. Selected features went through a feature selection process to further improve the method efficiency. Additionally, representative classifiers were trained and tested to measure the suitability of the proposed approach. The method was tested with a dataset of 285 OCT scans labeled by a specialist. In particular, 3,600 samples were equally extracted from the dataset, representing zones with and without ERM presence. Different experiments were conducted to reach the most suitable approach. Finally, selected classifiers were trained and compared using different metrics, providing in the best configuration an accuracy of 89.35%.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701536 | PMC |
http://dx.doi.org/10.1364/BOE.10.004018 | DOI Listing |
Sci Rep
January 2025
Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
To assess the choroidal vessels in healthy eyes using a novel three-dimensional (3D) deep learning approach. In this cross-sectional retrospective study, swept-source OCT 6 × 6 mm scans on Plex Elite 9000 device were obtained. Automated segmentation of the choroidal layer was achieved using a deep-learning ResUNet model along with a volumetric smoothing approach.
View Article and Find Full Text PDFJ Mol Cell Cardiol
December 2024
A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland; Heart Centre and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland. Electronic address:
Background: Coronary stenting operations have become the main option for the treatment of coronary heart disease. Vessel recovery after stenting has emerged as a critical factor in reducing possible complications. In this study, we evaluated the feasibility, safety and efficacy of locally administered intraluminal gene therapy delivered using a specialized infusion balloon catheter.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Background: Dementia is age-related with a significant genetic contribution, yet genome-wide association studies have not fully accounted for heritability. This discrepancy may in part be due to reliance on SNPs and small indels. Whole-genome sequencing (WGS) data in the Japanese population may reveal population-specific susceptibility loci for dementia.
View Article and Find Full Text PDFHeliyon
November 2024
Department of Mining Engineering, Faculty of Engineering, Hadimkoy Campus, Istanbul University - Cerrahpasa, 34500, Istanbul, Turkiye.
One of the challenges encountered in mining is acid mine drainage (AMD) in sulphurous ores in response to rainfall and groundwater. CPB one of the most prevalent waste management systems addresses this issue today. Nevertheless, in the long term, the concretion in CPB may become ineffective because of external factors, such as groundwater and rainfall.
View Article and Find Full Text PDFIntroduction: Hippocampal hyperactivity is a hallmark of prodromal Alzheimer's disease (AD) that predicts progression in patients with amnestic mild cognitive impairment (aMCI). AGB101 is an extended-release formulation of levetiracetam in the dose range previously demonstrated to normalize hippocampal activity and improve cognitive performance in aMCI. The HOPE4MCI study was a 78-week trial to assess the progression of MCI due to AD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!